FDA Approves New Treatment for Metastatic Pancreatic Cancer

The new frontline therapy is the first in a decade intended to treat aggressive pancreatic adenocarcinoma.

SciePro/Shutterstock

It’s been a long time coming, but a new frontline therapy for pancreatic cancer has been approved by the U.S. Food and Drug Administration (FDA).

While decades of cancer research have led to innovation and new medications for myriad types of cancer, new therapies have yet to be offered for pancreatic cancer until now, giving patients who suffer from it more treatment options.